期刊文献+

磷酸钙/硅酸钙/泡铋矿复合盖髓材料的细胞毒性和抑菌性评价 被引量:2

Evaluation on cytotoxicity and antimicrobial properties of calcium phosphate/calcium silicate/bismutite cement
下载PDF
导出
摘要 目的评价新型复合盖髓材料磷酸钙/硅酸钙/泡铋矿复合水门汀(calcium phosphate-calcium silicate-bismuth compound cement,CPCSBi)的细胞毒性和对常她口腔致龋菌的体外抑菌性能。方法采用琼脂覆盖法,比较CPCSBi和商品化盖髓材料Dycal、氢氧化钙糊剂(calcium hydroxide,CH)对人牙髓细胞的体外细胞毒性作用。采用琼脂扩散法,通过测量抑菌圈直径大小,评价CPCSBi与Dycal、CH对变形链球菌(Streptococcous mutans,Sm)、粘性放线杆菌(Actinomyces viscosus,Av)、嗜酸乳杆菌(Laetobacillus acidophilus,La)、金黄色葡萄球菌(Staphylococcus aureus,Sa)及白色念珠菌(Candida albicans,Ca)的抑菌效果。结果CPCSBi表现为轻度细胞毒性,Dycal和CH均显示中度细胞毒性。CPCSBi对Sm、Av、La和Sa具有良好的抑制作用,较Dycal和CH强5~10倍。结论CPCSBi仅有轻微的细胞毒性,但对口腔常见致龋菌的抑菌作用显著,具有进一步开发的潜能。 Objective The aim of this study was to evaluate cytotoxity and antimicrobal properties of new calcium phosphate/calcium silicate/bismutite (CPCSBi) cement. Methods Cytotoxity of CPCSBi was compared with those of cal- cium hydroxide (CH) and Dycal cements in dental pulpcapping applications by an agar overlay test in vitro. The diameters of bacterial inhibition zone of CPCSBi, CH and Dycal against Streptococcous mutans (Sin) , Actinomyces viscosus (Av) , Lactobacillus acidophilus (La) , Staphylococcus attreus (Sa) and Candida albicans (Ca) were determined by an agar dif- fusion test, respectively. Results Only slight cytotoxicity appeared for CPCSBi, whereas both CH and Dycal produced moderate discoloration and lysis. In antimicrobial tests against Sin, Av, La, and Sa, the antimicrobial potency of the CPCS- Bi was approximately 5-10 times greater than that of Dycal and CH groups. Conclusions These results suggest that CPCS- Bi possesses slight cytotoxity and high antimicrobial properties.
出处 《口腔材料器械杂志》 2012年第1期17-21,共5页 Chinese Journal of Dental Materials and Devices
基金 上海市重点学科(口腔基础医学)建设项目(No.S30206)
关键词 盖髓剂 磷酸钙/硅酸钙/泡铋矿 细胞毒性 抑菌性 Pulp-capping agent Calcium phosphate/calcium silicate/bismutite Cytotoxicity Antimicrobial
  • 相关文献

参考文献4

二级参考文献64

  • 1陈双厚 黄霞珍 等.海明愈疡膏抗炎镇痛化腐生肌作用实验研究[J].中药药理与临床,1997,13:86-86.
  • 2江明性.药理学[M].北京:人民卫生出版社,1992.81-82.
  • 3[1]Sun H, Sadler PJ. Bismuth antiulcer complexes. Top Biol Inorg Chem, 1999;2:159~185.
  • 4[2]Slikkerveer A, de Wolff FA. Pharmacokinetics and toxicity of bismuth compounds. Med Toxicol Adverse Drug Exp, 1989;4: 303-323.
  • 5[3]Menge H, Gregor M, Brosius B, et al. Pharmacology of bismuth.Eur J Gastroenterol Hepatol 1994, 4(S2): 41~47.
  • 6[4]J.W. Clitherow, United Kingdom Patent GB2220937A, 1990.
  • 7[5]McColm AA, McLaren A, Klinkert G, et al. Ranitidine bismuth citrate: a novel anti-ulcer agent with different physico-chemical characteristics and improved biological activity to a bismuth citrateranitidine admixture. Aliment Pharmacol Therap, 1996; 10:241~250.
  • 8[6]Sadler PJ, Sun H. Ranitidine bismuth citrate. J Chem Soc Dalton Trans, 1995;1395~1401.
  • 9[7]Warren JR, Marshall B, Unidentified curved bacilli on gastric epithelium in active chronic gastritis. Lancet, 1983; i: 1273~1275.
  • 10[8]Blaser MJ Hypotheses on the pathogenesis and natural history of Helicobacterpylori-induced inflammation. Gastroenterology, 1992;102:720~727.

共引文献35

同被引文献30

引证文献2

二级引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部